Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In melanoma patients refractory to antiPD-1 therapy, the combination of Talimogene laherparepvec (T-VEC), an oncolytic herpesvirus, with pembrolizumab (NCT04068181) showed enhanced systemic immune activation and tumor response
Blood (2018) 132(Supplement 1):661
Transcriptional modifications may lead to disease progression, as transcriptomic analysis of bronchoalveolar lavage from severe COVID-19 patients showed reduced IFN-responsive genes response, compared to blood
Riehemann K., Schneider S
US$ 25.50
US$ 20.16
US$ 26.61
US$ 24.36
US$ 22.56
US$ 24.65
